INT9296

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1982
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 100
Total Number 101
Disease Relevance 36.65
Pain Relevance 27.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PLEK) extracellular region (PLEK) cytoplasm (PLEK)
Anatomy Link Frequency
platelet 91
plasma 4
blood 2
coronary artery 2
macrophages 1
PLEK (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 776 100.00 Very High Very High Very High
antagonist 44 100.00 Very High Very High Very High
Dopamine 28 100.00 Very High Very High Very High
cINOD 566 99.96 Very High Very High Very High
adenocard 35 99.96 Very High Very High Very High
headache 14 99.76 Very High Very High Very High
diclofenac 303 99.38 Very High Very High Very High
antidepressant 86 99.36 Very High Very High Very High
Paracetamol 25 99.30 Very High Very High Very High
Potency 42 99.20 Very High Very High Very High
Disease Link Frequency Relevance Heat
Coronary Artery Disease 69 99.96 Very High Very High Very High
Coagulation Disorder 59 99.84 Very High Very High Very High
Acute Coronary Syndrome 258 99.78 Very High Very High Very High
Headache 19 99.76 Very High Very High Very High
INFLAMMATION 342 99.68 Very High Very High Very High
Myocardial Infarction 431 99.48 Very High Very High Very High
Cv General 3 Under Development 284 98.94 Very High Very High Very High
Death 161 98.44 Very High Very High Very High
Diabetes Mellitus 44 97.80 Very High Very High Very High
Stable Angina Pectoris 4 97.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This study examined the dose-response effect on inhibition of platelet aggregation by roxifiban (DMP754), a novel oral platelet GP IIb/IIIa receptor inhibitor, and its safety and tolerability in patients with a history of chronic stable angina pectoris.
Negative_regulation (inhibitor) of platelet in platelet associated with stable angina pectoris and angina
1) Confidence 0.57 Published 2003 Journal Am J Cardiovasc Drugs Section Abstract Doc Link 14727937 Disease Relevance 0.44 Pain Relevance 0.27
This supports the view that inhibition of platelet COX-1 by low doses is sufficient to explain the cardio-protective effect of aspirin observed in clinical trials [1].
Negative_regulation (inhibition) of platelet in platelet associated with aspirin
2) Confidence 0.57 Published 2004 Journal Thromb J Section Body Doc Link PMC331420 Disease Relevance 0.29 Pain Relevance 0.65
Thus, naproxen is associated with profound inhibition of prostacyclin but the possible CV hazard associated with this effect may be mitigated by a parallel profound and persistent suppression of platelet TXA2 (Capone et al 2004), which translates into a small CV protection or neutral effect (Hernández-Díaz et al 2006; Kearney et al 2006).
Negative_regulation (suppression) of platelet in platelet
3) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621416 Disease Relevance 0.15 Pain Relevance 0.36
Inhibition of human platelet cathepsin A by non-steroidal anti-inflammatory drugs--in vitro study.
Negative_regulation (Inhibition) of platelet in platelet associated with aspirin, inflammation and cinod
4) Confidence 0.57 Published 1996 Journal Pol J Pharmacol Section Title Doc Link 9112639 Disease Relevance 0.29 Pain Relevance 0.51
Adjunctive platelet GP IIb/IIIa blockade was administered in 45% of these PCI procedures.
Negative_regulation (blockade) of platelet in platelet
5) Confidence 0.57 Published 2000 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC59588 Disease Relevance 0.71 Pain Relevance 0.07
Thus, troponin predicts magnitude of clinical benefit from therapy with either platelet GP IIb/IIIa blockade or low molecular weight heparin.
Negative_regulation (blockade) of platelet in platelet
6) Confidence 0.57 Published 2000 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC59588 Disease Relevance 0.95 Pain Relevance 0.19
Adjunctive platelet glycoprotein IIb/IIIa blockade during percutaneous coronary intervention (PCI) reduces platelet-mediated adverse ischemic outcomes.
Negative_regulation (blockade) of platelet in platelet
7) Confidence 0.57 Published 1999 Journal Am. J. Cardiol. Section Abstract Doc Link 10468074 Disease Relevance 0.15 Pain Relevance 0.15
This benefit of platelet GP IIb/IIIa inhibition is additive to that conferred by aspirin and unfractionated heparin and is most evident in those patients undergoing early PCI (<72 h following enrollment) [23].
Negative_regulation (inhibition) of platelet in platelet associated with aspirin
8) Confidence 0.57 Published 2000 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC59588 Disease Relevance 0.75 Pain Relevance 0.11
Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?
Negative_regulation (blockade) of platelet in platelet associated with acute coronary syndrome
9) Confidence 0.57 Published 2000 Journal J Invasive Cardiol Section Title Doc Link 10731290 Disease Relevance 0.70 Pain Relevance 0.25
Primary outcome measure: Inhibition of serum thromboxane B(2) (TXB(2)), as a marker of platelet cyclooxygenase-1 (COX-1) inhibition, measured on Day 11.
Negative_regulation (inhibition) of platelet in platelet
10) Confidence 0.57 Published 2010 Journal Curr Med Res Opin Section Body Doc Link 20429831 Disease Relevance 0 Pain Relevance 0
We sought to identify predictors of adverse clinical outcomes in patients with unstable angina and to investigate whether these factors would predict the magnitude of benefit achieved with platelet glycoprotein IIb/IIIa inhibition.
Spec (whether) Negative_regulation (inhibition) of platelet in platelet associated with angina
11) Confidence 0.57 Published 2001 Journal Am. J. Cardiol. Section Abstract Doc Link 11524055 Disease Relevance 0.61 Pain Relevance 0.42
Heparin and FK633, a short-acting platelet glycoprotein IIb/IIIa inhibitor, were added to recirculated blood in one group (group F, n=5) whereas only heparin was used in controls (group C, n=5).
Negative_regulation (inhibitor) of platelet in platelet
12) Confidence 0.57 Published 2004 Journal Thromb. Res. Section Body Doc Link 15183042 Disease Relevance 0 Pain Relevance 0
A large proportion of patients (52%) was treated during the procedure by platelet IIb/IIIa receptor blockade.
Negative_regulation (blockade) of platelet in platelet
13) Confidence 0.57 Published 2002 Journal Catheter Cardiovasc Interv Section Abstract Doc Link 11870939 Disease Relevance 0.52 Pain Relevance 0.09
On the other hand, those compounds which elicit an almost complete (> 95%) and continuous suppression of platelet COX-1 may represent an exception.
Negative_regulation (suppression) of platelet in platelet
14) Confidence 0.57 Published 2008 Journal Int J Clin Pharmacol Ther Section Abstract Doc Link 18397691 Disease Relevance 0.10 Pain Relevance 0.24
Both doses of CS-706 inhibited COX-2 activity to a similar extent as naproxen, whereas neither dose of CS-706 showed meaningful inhibition of platelet COX-1.
Negative_regulation (inhibition) of platelet in platelet
15) Confidence 0.57 Published 2007 Journal Dig. Dis. Sci. Section Abstract Doc Link 17216336 Disease Relevance 0.38 Pain Relevance 0.04
In samples obtained from the same infant 4 months later, plasma drug levels were undetectable (<1 ng/mL) and the platelet serotonin levels were no longer reduced (12% increase from baseline).
Negative_regulation (reduced) of platelet in plasma
16) Confidence 0.57 Published 2003 Journal Pediatrics Section Body Doc Link 14595087 Disease Relevance 0 Pain Relevance 0
CONCLUSIONS: Acetaminophen, which is a weak inhibitor of platelet cyclooxygenase 1, has a dose-dependent antiaggregatory effect.
Negative_regulation (inhibitor) of platelet in platelet
17) Confidence 0.57 Published 2005 Journal Anesthesiology Section Body Doc Link 16192763 Disease Relevance 0 Pain Relevance 0
As a result of these studies, low dose aspirin should be the choice of prophylactic therapy aimed at the inhibition of platelet cyclooxygenase activity.
Negative_regulation (inhibition) of platelet in platelet associated with aspirin
18) Confidence 0.57 Published 1993 Journal Indian Heart J Section Abstract Doc Link 8365757 Disease Relevance 0.68 Pain Relevance 0.67
This decrease in the platelet IP3 content was positively correlated with a reduction in the number of 5HT2A receptor binding sites (Delorme et al 2004), which could be reflective of postsynaptic receptor down-regulation caused by SRI administration (Maes and Meltzer 1995; Duman 1999).
Negative_regulation (decrease) of platelet in platelet
19) Confidence 0.57 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2416754 Disease Relevance 0.21 Pain Relevance 0.44
Importantly, we have recently shown that the degree of COX-2 inhibition achieved by individual NSAIDs (an index of drug potency/exposure), that do not show functional suppression of platelet COX-1, is a determinant of the CV hazard associated with them (Patrignani et al 2008a, c).
Negative_regulation (suppression) of platelet in platelet associated with cinod and potency
20) Confidence 0.57 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621416 Disease Relevance 0.46 Pain Relevance 0.35

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox